Gene amplification in ductal carcinoma in situ of the breast
✍ Scribed by L. Burkhardt; T. J. Grob; I. Hermann; E. Burandt; M. Choschzick; F. Jänicke; V. Müller; C. Bokemeyer; R. Simon; G. Sauter; W. Wilczak; A. Lebeau
- Publisher
- Springer US
- Year
- 2009
- Tongue
- English
- Weight
- 359 KB
- Volume
- 123
- Category
- Article
- ISSN
- 0167-6806
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
Background. Ductal carcinoma in situ (DCIS) of the male breast is an uncommon disease, accounting for approximately 7% of all male breast carcinomas. Compared with invasive carcinomas of the breast, the prognosis associated with DCIS in men is excellent; however, clinical features, pathology, and tr
Ductal carcinoma in situ (DCIS) now accounts for 20-30% of all newly diagnosed breast cancers in centers which use mammographic surveillance as a standard part of the examination. The majority of these DCIS lesions, at least in the United States, are of very limited size, with mean estimated extents
## Abstract Ductal carcinoma in situ (DCIS) is increasing in frequency, primarily because of the increasing use of routine screening mammography. The management of DCIS has become one of the more controversial aspects in the treatment of breast cancer. Although total mastectomy provides local contr
Ductal carcinoma in situ (DCIS) was a relatively uncommon disease process when we relied on palpation to detect breast lesions. With the advent of more widespread mammography screenings, the surgeon is faced with a welcome opportunity to prevent cancer by dealing with a precursor lesion. Discovering